Drug and Alcohol Dependence
Volume 86, Issue 1 , Pages 22-29 , 5 January 2007

Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms

  • Alan J. Budney

      Affiliations

    • Department of Psychiatry, University of Arkansas for Medical Sciences, 4301 W. Markham, Little Rock, AR 72205, United States
    • Corresponding Author InformationCorresponding author at: 4301 W. Markham St., Slot 843, Little Rock, AR 72206, United States. Tel.: +1 501 686 5207; fax: +1 501 526 7816.
    • ,
  • Ryan G. Vandrey

      Affiliations

    • Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224, United States
    • ,
  • John R. Hughes

      Affiliations

    • Department of Psychiatry, University of Vermont College of Medicine, 38 Fletcher Place, Burlington, VT 05401, United States
    • ,
  • Brent A. Moore

      Affiliations

    • Department of Psychiatry, Yale University School of Medicine, 34 Park St., New Haven, CT 06519, United States
    • ,
  • Betsy Bahrenburg

      Affiliations

    • Department of Psychiatry, University of Vermont College of Medicine, 38 Fletcher Place, Burlington, VT 05401, United States

Received 15 February 2006 ,Revised 21 April 2006 ,Accepted 21 April 2006.

References 

  1. Budney AJ, Hughes JR. The cannabis withdrawal syndrome. Curr. Opin. Psychiatr. 2006;19:233–238
  2. Budney AJ, Hughes JR, Moore BA, Novy PL. Marijuana abstinence effects in marijuana smokers maintained in their usual living environment. Arch. Gen. Psychiatr. 2001;58:917–924
  3. Budney AJ, Hughes JR, Moore BA, Vandrey RG. A review of the validity and significance of the cannabis withdrawal syndrome. Am. J. Psychiatr. 2004;161:1967–1977
  4. Budney AJ, Moore BA, Vandrey RG, Hughes JR. The time course and significance of cannabis withdrawal. J. Abnorm. Psychol. 2003;112:393–402
  5. Budney AJ, Novy P, Hughes JR. Marijuana withdrawal among adults seeking treatment for marijuana dependence. Addiction. 1999;94:1311–1322
  6. Carskadon MA, Dement WC, Mitler MM, Guilleminault MD, Zarcone VD, Spiegel R. Self-reports versus sleep laboratory findings in 122 drug-free subjects with complaints of chronic insomnia. Am. J. Psychiatr. 1976;133:1382–1388
  7. Chait LD, Zacny JP. Reinforcing and subjective effects of oral delta-9-THC and smoked marijuana in humans. Psychopharmacology (Berl.). 1992;107:255–262
  8. Defonseca FR, Carrera MRA, Navarro M, Koob GF, Weiss F. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science. 1997;276:2050–2054
  9. Derogatis LR. Brief Symptom Inventory: Administration, Scoring and Procedures Manual. Minneapolis, MN: National Computer Systems Inc.; 1993;
  10. Diana M, Melis M, Muntoni AL, Gessa GL. Mesolimbic dopaminergic decline after cannabinoid withdrawal. Proc. Natl. Acad. Sci. U.S.A. 1998;95:10269–10273
  11. Elsohly MA, Dewit H, Wachtel SR, Feng S, Murphy TP. Delta9-tetrahydrocannabivarin as a marker for the ingestion of marijuana versus marinol: results of a clinical study. J. Anal. Toxicol. 2001;25:565–571
  12. Elsohly MA, Feng S, Murphy TP, Warrington AW, Ross S, Nimrod A, et al. Identification and quantitation of 11-nor-delta9-tetrahydrocannabivarin-9-carboxylic acid, a major metabolite of delta9-tetrahydrocannabivarin. J. Anal. Toxicol. 2001;25:476–480
  13. Haertzen CH, Hickey JE. ARCI: measurement of euphoria and other drug effects. In:  Bozarth MA editors. Methods for Assessing the Reinforcing Properties of Abused Drugs. New York: Springer-Verlag; 1987;p. 489–524
  14. Haney M, Comer SD, Ward AS, Foltin RW, Fischman MW. Abstinence symptoms following oral THC administration to humans. Psychopharmacology (Berl.). 1999;14:385–394
  15. Haney M, Hart CL, Vosburg SK, Nasser J, Bennett A, Zubaran C, et al. Marijuana withdrawal in humans: effects of oral THC or Divalproex. Neuropsychopharmacology. 2004;29:158–170
  16. Haney M, Hart CL, Ward AS, Foltin RW. Nefazodone decreases anxiety during marijuana withdrawal in humans. Psychopharmacology (Berl.). 2003;165:157/165
  17. Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW. Abstinence symptoms following smoked marijuana in humans. Psychopharmacology (Berl.). 1999;14:395–404
  18. Haney M, Ward AS, Comer SD, Hart CL, Foltin RW, Fischman MW. Bupropion SR worsens mood during marijuana withdrawal in humans. Psychopharmacology (Berl.). 2001;155:171–179
  19. Hart CL. Increasing treatment options for cannabis dependence: a review of potential pharmacotherapies. Drug Alcohol Depend. 2005;80:147–159
  20. Hart CL, Haney M, Vosburg SK, Comer SD, Foltin RW. Reinforcing effects of oral ▴9-THX in male marijuana smokers in a laboratory choice procedure. Psychopharmacology (Berl.). 2005;181(12):237–243
  21. Heishman SJ, Singleton EG, Ligouri A. Marijuana craving questionnaire: development and initial validation of a self-report instrument. Addiction. 2001;96:1023–1034
  22. Hudziak JJ, Helzer JE, Wetzel MW. The use of the DSM-III-R Checklist for initial diagnostic assessments. Comp. Psychiatr. 1993;34:375–383
  23. Huestis MA, Cone EJ. Differentiating new marijuana use from residual drug excretion in occasional marijuana users. J. Anal. Toxicol. 1998;22:445–454
  24. Hughes, J.R., in press. Effects of Abstinence from Tobacco: Valid Symptoms and Time Course. Nicotine and Tabacco Research.
  25. In:  Hughes JR,  Higgins ST,  Hatsukami D editor. Effects of Abstinence from Tobacco: A Critical Review. New York: Plenum Press; 1990;
  26. Jones RT, Benowitz N. The 30-day trip: clinical studies of cannabis tolerance and dependence. In:  Braude MC,  Szara S editor. Pharmacology of Marihuana. New York: Raven Press; 1976;p. 627–642
  27. Koob GF, Lemoal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology. 2001;24:97–129
  28. Kouri EM, Pope HG. Abstinence symptoms during withdrawal from chronic marijuana use. Exp. Clin. Psychopharmacol. 2000;8:483–492
  29. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Bohme GA, et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science. 1999;283:401–404
  30. Levin FR, Mcdowell D, Evans SM, Nunes E, Akerele E, Donovan S, et al. Pharmacotherapy for marijuana dependence: a double-blind, placebo-controlled pilot study of divalproex sodium. Am. J. Addict. 2004;13:21–32
  31. Lichtman AH, Martin BR. Marijuana withdrawal syndrome in the animal model. J. Clin. Pharmacol. 2002;42:20S–27S
  32. Mcnair DM, Lorr M, Droppleman LF. Manual for the Profile of Mood States. San Diego: Educational and Industrial Testing Service; 1971;
  33. Mcrae AL, Budney AJ, Brady KT. Treatment of marijuana dependence: a review of the literature. J. Subst. Abuse Treat. 2003;24:369–376
  34. Stephens RS, Babor TF, Kadden R, Miller M The Marijuana Treatment Project Research Group. The marijuana treatment project: rationale, design, and participant characteristics. Addiction. 2002;97:109–124
  35. Valverde O, Maldonado R, Valjent E, Zimmer AM, Zimmer A. Cannabinoid withdrawal syndrome is reduced in pre-proenkephalin knock-out mice. J. Neurosci. 2000;20:9284–9289
  36. Vandrey R, Budney AJ, Kamon JL, Stanger C. Cannabis withdrawal in adolescent treatment seekers. Drug Alcohol Depend. 2005;78:205–210
  37. Young SE, Corley RP, Stallings MC, Rhee SH, Crowley TJ, Hewitt JK. Substance use, abuse and dependence in adolescents: prevalence, symptoms profiles and correlates. Drug Alcohol Depend. 2002;68:309–322

PII: S0376-8716(06)00180-3

doi: 10.1016/j.drugalcdep.2006.04.014

Drug and Alcohol Dependence
Volume 86, Issue 1 , Pages 22-29 , 5 January 2007

Article Tools

* Image Usage & Resolution